Expedient removal of dying, damaged or altered cells by phagocytosis is essential for homeostasis. However, cancer cells can evade such phagocytic elimination by cell surface-upregulation of phagocyte-inhibitory signals, such as CD47. CD47 is a prominent "don't eat me" signal that binds to signal-regulatory protein alpha (SIRPα) expressed on phagocytes (Oldenborg et al, 2001) . The CD47-SIRPα interaction triggers phosphorylation of the immunoreceptor tyrosine-based inhibition motif (ITIM) of SIRPα and thereby potently inhibits phagocyte activity. Both solid and hematologic malignancies hijack this inhibitory pathway by overexpression of CD47 Chao et al, 2010) . Recent studies highlight that blocking of CD47-SIRPα interaction promotes phagocytic elimination of CD47 overexpressing tumor cells (Chao et al, 2010; Kim et al, 2012) . For instance, treatment of human B-cell non-Hodgkin lymphomas (B-NHL)-engrafted mice with CD47-blocking MAb B6H12 reduced lymphoma burden and improved survival. Further combination of this CD47-blocking antibody with the therapeutic antibody rituximab (RTX; a chimeric anti-CD20 IgG1) triggered synergistic anticancer activity in vivo (Chao et al, 2010) . Thus, CD47-SIRPα blocking strategies can enhance the efficacy of anticancer antibodies. Phagocytosis induced by RTX was also enhanced by F(ab') 2 fragments of MAb B6H12 (Chao et al, 2010) . This finding opens up the possibility for design of immunotherapeutics that combine CD47 blockade with alternate effector moieties. Here, we explored this possibility by genetic fusion of a CD47-blocking antibody fragment (scFv) to the pro-apoptotic immune effector molecule TRAIL (TNF-related apoptosis-inducing ligand). TRAIL is a death ligand of the TNF-ligand superfamily that has pronounced tumor-selective pro-apoptotic activity (reviewed in (Bremer et al, 2009) ). In phase I clinical trials, TRAIL treatment triggered minimal toxicity and, in combination with RTX, produced clinical responses in B-NHL patients (Fox et al, 2010) . This new fusion protein, designated antiCD47:TRAIL, was designed to 1) block CD47-SIRPα interaction and hereby potentiate phagocytosis induced by RTX, and 2) concurrently trigger CD47-restricted apoptotic cell death in malignant B-cells. To assess the effect of antiCD47:TRAIL on RTX-induced phagocytosis, we performed mixed culture experiments with B-NHL cells and granulocytes as phagocytic effector cells as they are one of the most prevalent population of professional phagocytes. To this end, DiD-labeled CD20 + / CD47 + B-NHL cells ( Fig.  S1A -B) were mixed with granulocytes and incubated in the presence of RTX, MAb B6H12 or antiCD47:TRAIL and combinations thereof. Subsequently, phagocytosis was determined by flow cytometry (see Fig.S1C for gating strategy). Treatment with RTX induced rapid phagocytosis of CD20 + B-NHL cells, whereas treatment with antiCD47:TRAIL alone did not (Fig.1A) . However, co-treatment with RTX and antiCD47:TRAIL significantly increased tumor cell phagocytosis compared to RTX alone (Fig.1A, p<0 .05). These flow cytometry data were corroborated by microscopy data, which revealed prominent tumor cell engulfment by granulocytes upon co-treatment (Fig.1B) . The potentiating effect of antiCD47:TRAIL on RTX-mediated phagocytosis was dose-dependent and apparent at low ng/ml concentrations of antiCD47:TRAIL (Fig.1C ). Importantly, antiCD47:TRAIL also enhanced phagocytic removal of primary patient-derived B-NHL cells ( Fig.1D ).
Of note, at these low ng/ml concentrations MAb B6H12 did not potentiate RTX-induced phagocytosis (Fig.1A-D) , which is in apparent contrast with a previous report in which MAb B6H12 did synergize RTX-mediated phagocytosis (Chao et al, 2010) . However, in our experiments we used significantly lower concentrations of both RTX and MAb B6H12 (RTX; 2.5 vs. 10 ug/ml, mAb CD47; 250ng vs. 10 ug/ml, respectively). Further, we used granulocytes as phagocytic effector cells, whereas Chao et al used macrophages. Third, TRAIL forms a stable homotrimer in scFv:TRAIL proteins (Bremer et al, 2004) . Hence, trivalent binding by antiCD47:TRAIL may result in a significantly higher CD47 blocking capacity compared with the bivalent blocking capacity of MAb B6H12. Phagocytosis induction by RTX and anti-CD47:TRAIL was abrogated at 0°C, indicating that tumor cells were eliminated by active phagocytosis (Fig.1E ). Furthermore, co-treatment of CD20-Namalwa cells with RTX and antiCD47:-TRAIL did not enhance phagocytosis. Likewise, co-treatment of B-cell lines with antiCD47:TRAIL and cetuximab (CTX; a chimeric anti-EGFR IgG 1 ) failed to enhance phagocytosis (Fig.1F) . Thus, antiCD47:TRAIL selectively enhanced antibody-mediated phagocytosis of B-NHL cells by RTX in a target antigen-restricted manner.
Previously, we and others demonstrated that scFv:TRAIL fusion proteins have target antigen-restricted pro-apoptotic activity towards cancer cells (reviewed in (Bremer et al, 2009) ). In line with this, antiCD47:TRAIL triggered apoptosis in CD47+ B-cell lines and in 4 of 5 primary malignant B-NHL samples ( Fig.2A,  2B) . Importantly, normal blood cells were fully resistant to treatment with an-tiCD47:TRAIL (Fig.2B ). Furthermore, antiCD47:TRAIL potentiated RTX-media- ted pro-apoptotic activity in the presence of granulocytes (Fig.2C ).
In line with published data, treatment with MAb B6H12 alone did not induce apoptosis ( Fig.2A) (Chao et al, 2010) . Nevertheless, CD47 cross-linking by other anti-CD47 antibodies was reported to trigger caspase-independent cell death. In this respect, a bivalent form of the antibody fragment used in antiCD47:-TRAIL was previously shown to trigger CD47-mediated apoptosis in B-NHL cells (Kikuchi et al, 2004) . Thus, antiCD47:TRAIL may have dual pro-apoptotic signaling capacity via CD47 cross-linking (caspase-independent) and via target-antigen restricted cross-linking of agonistic TRAIL-receptors (caspase-dependent). In line with this, apoptotic activity of antiCD47:TRAIL was only partly blocked by pan-caspase inhibitor zVAD-fmk, whereas the pro-apoptotic activity of a constitutively active TRAIL preparation was completely blocked ( Fig 2D) . Furthermore, TRAIL-neutralizing MAb 2E5 only partly inhibited apoptosis induction by antiCD47:TRAIL (Fig.2D ). Thus, antiCD47:TRAIL appears to concurrently trigger apoptosis via CD47-crosslinking and TRAIL-receptor signaling. As CD47 is widely expressed, the use of therapeutic intact humanized or chimerized anti-CD47 antibodies of selected isotypes may trigger toxicity towards normal cells by antibody-dependent cellular cytotoxicity and/or antibody-dependent cellular phagocytosis. In contrast, antiCD47:TRAIL inhibits CD47-SI-RPα interactions without this potential risk for Fc-mediated toxicity.
In conclusion, antiCD47:TRAIL effectively blocks CD47-mediated "don't eat me" signaling, promotes RTX-induced phagocytosis by granulocytes and triggers CD47-restricted apoptosis in malignant B-cells (for schematic see Fig.2E ). This multifunctional therapeutic activity of antiCD47:sTRAIL may be of general use for optimizing antibody-based cancer therapy and serves as proof of concept for combining CD47-blockade with alternate effector principles that may further synergize anticancer activity.
